相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients
S. Georgin-Lavialle et al.
BRITISH JOURNAL OF DERMATOLOGY (2022)
Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry
Thibault Comont et al.
BRITISH JOURNAL OF HAEMATOLOGY (2022)
Phagocytosis checkpoints on hematopoietic stem cells in patients with myelodysplastic syndromes
Xifeng Dong et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2022)
Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis
Teng Gao et al.
NATURE COMMUNICATIONS (2021)
Therapeutic options in VEXAS syndrome: insights from a retrospective series
Estelle Bourbon et al.
BLOOD (2021)
Novel somatic mutations in UBA1 as a cause of VEXAS syndrome
James A. Poulter et al.
BLOOD (2021)
Development of luspatercept to treat ineffective erythropoiesis
Anne Sophie Kubasch et al.
BLOOD ADVANCES (2021)
Myelodysplastic syndrome patients display alterations in their immune status reflected by increased PD-L1-expressing stem cells and highly dynamic exhausted T-cell frequencies
Wiebke Moskorz et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
High mutation burden in the checkpoint and micro-RNA processing genes in myelodysplastic syndrome
Ivan Sergeevich Moiseev et al.
PLOS ONE (2021)
Comorbidities and frailty predict outcome of patients with myelodysplastic syndromes. Should we integrate them in novel prognostic scoring systems?
Thomas P. Thomopoulos et al.
JOURNAL OF GERIATRIC ONCOLOGY (2021)
Myelodysplastic syndrome and immunotherapy novel to next in-line treatments
Katherine Linder et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)
Natural Killer Cell Subpopulations and Inhibitory Receptor Dynamics in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Vlad Andrei Cianga et al.
FRONTIERS IN IMMUNOLOGY (2021)
Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome
Kelly S. Chien et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Abnormal Macrophage Polarization in Patients with Myelodysplastic Syndrome
Gaochao Zhang et al.
MEDIATORS OF INFLAMMATION (2021)
Myeloid-Derived Suppressor Cells and Mesenchymal Stem/Stromal Cells in Myeloid Malignancies
Suncica Kapor et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1
Ifeyinwa Emmanuela Obiorah et al.
BLOOD ADVANCES (2021)
CD8+ T cells exhaustion induced by myeloid-derived suppressor cells in myelodysplastic syndromes patients might be through TIM3/Gal-9 pathway
Jinglian Tao et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
Pierre Fenaux et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
Mark P. Chao et al.
FRONTIERS IN ONCOLOGY (2020)
Bone Marrow Monocytes and Derived Dendritic Cells from Myelodysplastic Patients Have Functional Abnormalities Associated with Defective Response to Bacterial Infection
Laiz C. Bento et al.
JOURNAL OF IMMUNOLOGY (2020)
The Nlrp3 inflammasome as a rising star in studies of normal and malignant hematopoiesis
Mariusz Z. Ratajczak et al.
LEUKEMIA (2020)
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management
Guillermo Garcia-Manero et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
David A. Sallman et al.
BLOOD (2020)
TLR2/6 signaling promotes the expansion of premalignant hematopoietic stem and progenitor cells in the NUP98-HOXD13 mouse model of MDS
Darlene A. Monlish et al.
EXPERIMENTAL HEMATOLOGY (2020)
Contribution of Aberrant Toll Like Receptor Signaling to the Pathogenesis of Myelodysplastic Syndromes
Luana Chiquetto Paracatu et al.
FRONTIERS IN IMMUNOLOGY (2020)
Overexpression of TIGIT in NK and T Cells Contributes to Tumor Immune Escape in Myelodysplastic Syndromes
Fanqiao Meng et al.
FRONTIERS IN ONCOLOGY (2020)
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents
Carsten Riether et al.
NATURE MEDICINE (2020)
Myelodysplastic Syndromes
Mario Cazzola
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease
David B. Beck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A Phase 1/1b Safety Study of Prgn-3006 Ultracar-T™ in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome
David A. Sallman et al.
BLOOD (2020)
Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients
David A. Sallman et al.
BLOOD (2020)
A Phase 1, Open Label Dose Escalation Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Guillermo Garcia-Manero et al.
BLOOD (2020)
A Phase 1 Study of NKX101, an Allogeneic CAR Natural Killer (NK) Cell Therapy, in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndrome (MDS)
Carlos Bachier et al.
BLOOD (2020)
A Phase II Study of Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS)
Kiyomi Morita et al.
BLOOD (2020)
GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts
Erica D. Warlick et al.
BLOOD (2020)
The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML)
Amer M. Zeidan et al.
BLOOD (2020)
MDS/CMML with TET2 or IDH mutation Are Associated with Systemic Inflammatory and Autoimmune Diseases (SIAD) and T Cell Dysregulation
Lin-Pierre Zhao et al.
BLOOD (2020)
Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study
Andrew M. Brunner et al.
BLOOD (2020)
Therapeutic Cancer Vaccination Targeting Shared Tumor Associated Antigens in Combination with Azacitidine for High Risk Myelodysplastic Syndrome - a Phase I Clinical Trial
Staffan Holmberg-Thyden et al.
BLOOD (2020)
Circulating S100A8 and S100A9 protein levels in plasma of patients with acquired aplastic anemia and myelodysplastic syndromes
Valentina Giudice et al.
CYTOKINE (2019)
The Molecular Pathology of Myelodysplastic Syndrome
Torsten Haferlach
PATHOBIOLOGY (2019)
The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes
David A. Sallman et al.
BLOOD (2019)
Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling
Daniel A. Pollyea et al.
HAEMATOLOGICA (2019)
S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes
Pinyang Cheng et al.
LEUKEMIA (2019)
Flaming and fanning: The Spectrum of inflammatory influences in myelodysplastic syndromes
Titas Banerjee et al.
BLOOD REVIEWS (2019)
CD123 CAR T cells for the treatment of myelodysplastic syndrome
Brett M. Stevens et al.
EXPERIMENTAL HEMATOLOGY (2019)
Managing post allograft relapse of myeloid neoplasms: azacitidine and donor lymphocyte infusions as salvage therapy
John Claiborne et al.
LEUKEMIA & LYMPHOMA (2019)
The inflammatory cytokine profile of myelodysplastic syndromes A meta-analysis
Xin Shi et al.
MEDICINE (2019)
U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies
Molly A. Smith et al.
NATURE CELL BIOLOGY (2019)
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study
Farhad Ravandi et al.
LANCET HAEMATOLOGY (2019)
Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS
Eric Huselton et al.
BLOOD (2019)
A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results
Amer M. Zeidan et al.
BLOOD (2019)
Prognostic impact of peripheral blood WT1-mRNA expression in patients with MDS
Christina Rautenberg et al.
BLOOD CANCER JOURNAL (2019)
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia
Patrick Williams et al.
CANCER (2019)
Retuning the immune system in myelodysplastic syndromes: from immunomodulatory approaches to vaccination strategies and non myeloablative hemopoietic cell transplant
Claudio Fozza
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
David A. Sallman et al.
BLOOD (2019)
Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study
Amer M. Zeidan et al.
BLOOD (2019)
Inflammatory cytokines promote clonal hematopoiesis with specific mutations in ulcerative colitis patients
Christine R. C. Zhang et al.
EXPERIMENTAL HEMATOLOGY (2019)
Comorbid and inflammatory characteristics of genetic subtypes of clonal hematopoiesis
Elina K. Cook et al.
BLOOD ADVANCES (2019)
Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab
Catherine Lai et al.
BLOOD ADVANCES (2019)
The emerging role of immune checkpoint based approaches in AML and MDS
Prajwal Boddu et al.
LEUKEMIA & LYMPHOMA (2018)
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure
Amer M. Zeidan et al.
CLINICAL CANCER RESEARCH (2018)
A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome
Fevzi Firat Yalniz et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Immune dysregulation in myelodysplastic syndrome: Clinical features, pathogenesis and therapeutic strategies
Cong Wang et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)
An inflammatory environment containing TNFα favors Tet2-mutant clonal hematopoiesis
Samuel O. Abegunde et al.
EXPERIMENTAL HEMATOLOGY (2018)
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
Remy Thomas et al.
FRONTIERS IN IMMUNOLOGY (2018)
Age and Age-Related Diseases: Role of inflammation Triggers and Cytokines
Irene Maeve Rea et al.
FRONTIERS IN IMMUNOLOGY (2018)
Heterogeneous Responses of Hematopoietic Stem Cells to Inflammatory Stimuli Are Altered with Age
Mati Mann et al.
CELL REPORTS (2018)
PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis
Aaron T. Gerds et al.
BLOOD (2018)
Phase I Results of a Multicenter Clinical Trial Combining Guadecitabine, a DNA Methyltransferase Inhibitor, with Atezolizumab, an Immune Checkpoint Inhibitor, in Patients with Relapsed or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Casey L. O'Connell et al.
BLOOD (2018)
A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS)
Guillermo Garcia-Manero et al.
BLOOD (2018)
A Clinical Study of Tomaralimab (OPN-305), a Toll-like Receptor 2 (TLR-2) Antibody, in Heavily Pre-Treated Transfusion Dependent Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received and Failed on Prior Hypomethylating Agent (HMA) Therapy
Guillermo Garcia-Manero et al.
BLOOD (2018)
NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome
Elizabeth A. Griffiths et al.
CLINICAL CANCER RESEARCH (2018)
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort
Maximilian Stahl et al.
BLOOD ADVANCES (2018)
161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS
Dhifaf Sarha et al.
BLOOD ADVANCES (2018)
Chronic immune response dysregulation in MDS pathogenesis
Laura Barreyro et al.
BLOOD (2018)
Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis
F. Thol et al.
LEUKEMIA (2017)
The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer
Hanke L. Matlung et al.
IMMUNOLOGICAL REVIEWS (2017)
Interleukin-8 and nuclear factor kappa B are increased and positively correlated in myelodysplastic syndrome
Anacelia Gomes de Matos et al.
MEDICAL ONCOLOGY (2017)
Dnmt3a restrains mast cell inflammatory responses
Cristina Leoni et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice
Jose J. Fuster et al.
SCIENCE (2017)
Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes
Toshio Asayama et al.
ONCOTARGET (2017)
Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia
Anne M. Dickinson et al.
FRONTIERS IN IMMUNOLOGY (2017)
Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia
Sebastien Anguille et al.
BLOOD (2017)
Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29 patients
Arsene Mekinian et al.
AUTOIMMUNITY REVIEWS (2017)
PD-1 signaling and inhibition in AML and MDS
Faysal Haroun et al.
ANNALS OF HEMATOLOGY (2017)
KIR gene haplotype: an independent predictor of clinical outcome in MDS patients
Kate Stringaris et al.
BLOOD (2016)
The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype
Ashley A. Basiorka et al.
BLOOD (2016)
The immune landscape of myelodysplastic syndromes
Claudio Fozza et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Natural Killer Cell (NK) Subsets and NK-Like T-Cell Populations in Acute Myeloid Leukemias and Myelodysplastic Syndromes
N. Aggarwal et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2016)
Clonal Hematopoiesis of Indeterminate Potential A Risk Factor for Hematologic Neoplasms
Michael Heuser et al.
DEUTSCHES ARZTEBLATT INTERNATIONAL (2016)
Apoptosis in human myelodysplastic syndrome CD34+cells is modulated by the upregulation of TLRs and histone H4 acetylation via a β-arrestin 1 dependent mechanism
Qing Zeng et al.
EXPERIMENTAL CELL RESEARCH (2016)
Increased TIM3+CD8+T cells in Myelodysplastic Syndrome patients displayed less perforin and granzyme B secretion and higher CD95 expression
Jinglian Tao et al.
LEUKEMIA RESEARCH (2016)
Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores
Xing Liu et al.
NATURE (2016)
Chronic Infection Depletes Hematopoietic Stem Cells through Stress-Induced Terminal Differentiation
Katie A. Matatall et al.
CELL REPORTS (2016)
Monocyte-Derived Macrophages Are Impaired in Myelodysplastic Syndrome
Yu Han et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2016)
Pembrolizumab, a PD-1 Inhibitor, in Patients with Myelodysplastic Syndrome (MDS) after Failure of Hypomethylating Agent Treatment
Guillermo Garcia-Manero et al.
BLOOD (2016)
WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides
Jason Brayer et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance
Brian Kwok et al.
BLOOD (2015)
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
David P. Steensma et al.
BLOOD (2015)
Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromes
Maryam Hejazi et al.
HAEMATOLOGICA (2015)
Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death
Jianjin Shi et al.
NATURE (2015)
Lenalidomide induces ubiquitination and degradation of CK1a in del(5q) MDS
Jan Kroenke et al.
NATURE (2015)
Regulation of Toll-like Receptor Signaling by the SF3a mRNA Splicing Complex
Brian P. O'Connor et al.
PLOS GENETICS (2015)
Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromes
Maryam Hejazi et al.
HAEMATOLOGICA (2015)
Clinical Course and Management of Surgical Emergency in a Severe Hemophilia a Patient Under Weekly Subcutaneous Administration of a Bispecific Antibody to Factors IXa and X (ACE910)
Takeshi Kanematsu et al.
BLOOD (2015)
Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study
Aristoteles Giagounidis et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction
Rami S. Komrokji et al.
HAEMATOLOGICA (2014)
Advances in NKG2D ligand recognition and responses by NK cells
Nina Le Bert et al.
IMMUNOLOGY AND CELL BIOLOGY (2014)
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
H. Yang et al.
LEUKEMIA (2014)
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
T. Haferlach et al.
LEUKEMIA (2014)
Elevated TIM3+hematopoietic stem cells in untreated myelodysplastic syndrome displayed aberrant differentiation, overproliferation and decreased apoptosis
Tao Jing-lian et al.
LEUKEMIA RESEARCH (2014)
Age-related mutations associated with clonal hematopoietic expansion and malignancies
Mingchao Xie et al.
NATURE MEDICINE (2014)
Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis
Rajasekhar N. V. S. Suragani et al.
NATURE MEDICINE (2014)
Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
Giulio Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Outcome of Donor Lymphocyte Infusion after T Cell-depleted Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndromes
Pramila Krishnamurthy et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil et al.
BLOOD (2013)
Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome
Garrett W. Rhyasen et al.
CANCER CELL (2013)
Interleukin-17 enhances the production of interferon- and tumour necrosis factor- by bone marrow T lymphocytes from patients with lower risk myelodysplastic syndromes
Zheng Zhang et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2013)
Erythropoietin critically regulates the terminal maturation of murine and human primitive erythroblasts
Jeffrey Malik et al.
HAEMATOLOGICA (2013)
Impaired clearance of apoptotic cells leads to HMGB1 release in the bone marrow of patients with myelodysplastic syndromes and induces TLR4-mediated cytokine production
Maria Velegraki et al.
HAEMATOLOGICA (2013)
Induction of myelodysplasia by myeloid-derived suppressor cells
Xianghong Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Toll-like receptor alterations in myelodysplastic syndrome
Y. Wei et al.
LEUKEMIA (2013)
Bone marrow dendritic cells are reduced in patients with high-risk myelodysplastic syndromes
Leonie Saft et al.
LEUKEMIA RESEARCH (2013)
Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
Eyal C. Attar et al.
LEUKEMIA RESEARCH (2013)
IL10 inversely correlates with the percentage of CD8+ cells in MDS patients
Matheus Rodrigues Lopes et al.
LEUKEMIA RESEARCH (2013)
CD47 is expressed abnormally on hematopoietic cells in myelodysplastic syndrome
Huijuan Jiang et al.
LEUKEMIA RESEARCH (2013)
Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms
Ayana Kon et al.
NATURE GENETICS (2013)
Overexpression of the Toll-Like Receptor (TLR) Signaling Adaptor MYD88, but Lack of Genetic Mutation, in Myelodysplastic Syndromes
Sophie Dimicoli et al.
PLOS ONE (2013)
S100A8 and S100A9 Induce Cytokine Expression and Regulate the NLRP3 Inflammasome via ROS-Dependent Activation of NF-kappa B
Jean-Christophe Simard et al.
PLOS ONE (2013)
Pre-Treatment WT1 mRNA Expression Level In Peripheral Blood Predicts Response and Overall Survival Of Myelodysplastic Syndrome Patients In The Azacitidine Era
Tomoyasu Jo et al.
BLOOD (2013)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
T cells of patients with myelodysplastic syndrome are frequently derived from the malignant clone
Suzanne M. Vercauteren et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest
E. Sick et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group
Frederic Baron et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Expansion of Effector Memory Regulatory T Cells Represents a Novel Prognostic Factor in Lower Risk Myelodysplastic Syndrome
Adam W. Mailloux et al.
JOURNAL OF IMMUNOLOGY (2012)
IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes
A. Pardanani et al.
LEUKEMIA (2012)
Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia
Djordje Atanackovic et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
Pierre Fenaux et al.
BLOOD (2011)
Th17 and Foxp3+ T regulatory cell dynamics and distribution in myelodysplastic syndromes
Irene Bouchliou et al.
CLINICAL IMMUNOLOGY (2011)
Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies
Katayoun Rezvani et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Immunosuppressive Therapy for Patients With Myelodysplastic Syndrome: A Prospective Randomized Multicenter Phase III Trial Comparing Antithymocyte Globulin Plus Cyclosporine With Best Supportive Care-SAKK 33/99
Jakob R. Passweg et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Chronic Exposure to a TLR Ligand Injures Hematopoietic Stem Cells
Brandt L. Esplin et al.
JOURNAL OF IMMUNOLOGY (2011)
Frequent pathway mutations of splicing machinery in myelodysplasia
Kenichi Yoshida et al.
NATURE (2011)
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Rafael Bejar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
Padmanee Sharma et al.
NATURE REVIEWS CANCER (2011)
Interferon-γ and tumor necrosis factor-α induce an immunoinhibitory molecule, B7-H1, via nuclear factor-κB activation in blasts in myelodysplastic syndromes
Asaka Kondo et al.
BLOOD (2010)
Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept
Bart L. Scott et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells
Yoshikane Kikushige et al.
CELL STEM CELL (2010)
A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS
Ulrich Keilholz et al.
BLOOD (2009)
IL-17-producing CD4+ T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome
Shahram Y. Kordasti et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
Ravindra Majeti et al.
CELL (2009)
Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplasticsyndromes (MDS)
I. Kotsianidis et al.
LEUKEMIA (2009)
Pyroptosis: host cell death and inflammation
Tessa Bergsbaken et al.
NATURE REVIEWS MICROBIOLOGY (2009)
Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs
Dana E. Rollison et al.
BLOOD (2008)
The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes
Apostolia Maria Tsimberidou et al.
CANCER (2008)
Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies
Katayoun Rezvani et al.
BLOOD (2008)
Immature and mature monocyte-derived dendritic cells in myelodysplastic syndromes of subtypes refractory anemia or refractory anemia with ringed sideroblasts display an altered cytokine profile
Ling Ma et al.
LEUKEMIA RESEARCH (2007)
CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS)
Shahram Y. Kordasti et al.
BLOOD (2007)
Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin
Z. Y. Lim et al.
LEUKEMIA (2007)
Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors
Pearlie K. Epling-Burnette et al.
BLOOD (2007)
Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome
P. K. Epling-Burnette et al.
LEUKEMIA (2007)
Toll-like receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased apoptosis in myelodysplastic syndromes
Christos I. Maratheftis et al.
CLINICAL CANCER RESEARCH (2007)
Treatment of myelodysplastic syndrome with cyclosporin A
Shuchang Chen et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2007)
Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment
Yoshinori Nagai et al.
IMMUNITY (2006)
Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis
G Stifter et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2005)
Circulating myeloid and lymphoid precursor dendritic cells are clonally involved in myelodysplastic syndromes
L Ma et al.
LEUKEMIA (2004)
Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System score in patients with myelodysplastic syndromes
D Cilloni et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression
JN Kochenderfer et al.
BLOOD (2002)
分享论文
